IP Library Granted Patent US 9,765,304
Granted Patent B2
US 9,765,304 · App. 14/163,315 · Granted Sep 19, 2017

Synthetic viruses and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,765,304
App. No.
14/163,315
Granted
Sep 19, 2017
Kind
B2
Abstract

The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject. In a more preferred embodiment, the invention is based, generally, on compositions using synthetic viral particles as an adjuvant and/or vehicle to raise an immune response against selected antigen(s) or epitopes, in particular a cellular and/or a humoral immune response.

Claims (20)

1. An immunogenic composition comprising a non-infectious synthetic retroviral particle comprising:

a core comprising a polypeptide consisting of a self-assembling Gag protein of a particular retrovirus; and

a lipid bilayer envelope comprising one or more selected peptide antigens heterologous to any retrovirus;

wherein the one or more selected peptide antigens are exposed at the surface of the particle;

wherein the non-infectious synthetic retroviral particle is devoid of any retroviral genome; and

wherein the non-infectious synthetic retroviral particle is devoid of envelope protein of the particular retrovirus.

2. The immunogenic composition of claim 1 , comprising at least about 10 2 to about 10 9 of the synthetic retroviral particles.

3. The immunogenic composition of claim 1 , wherein the synthetic retroviral particle is devoid of envelope protein of any retrovirus.

4. The immunogenic composition of claim 1 , wherein the particular retrovirus is an onco-retrovirus or a spumavirus.

5. The immunogenic composition of claim 4 , wherein the particular retrovirus is not HIV.

6. The immunogenic composition of claim 1 , wherein the one or more selected peptide antigen is a glycopeptide antigen.

7. The immunogenic composition of claim 2 , wherein the one or more selected peptide antigen naturally comprises at least a portion of a transmembrane domain.

8. The immunogenic composition of claim 2 , wherein the one or more selected peptide antigen comprises a synthetic peptide.

9. The immunogenic composition of claim 8 , wherein the synthetic peptide is between 3 and 60 amino acids in length.

10. The immunogenic composition of claim 1 , further comprising a pharmaceutically acceptable vehicle.

11. The immunogenic composition of claim 10 , further comprising an adjuvant.

12. The composition of claim 1 , wherein the composition induces an immune response to the one or more selected peptide antigens.

13. A method of stimulating an immune response in a subject, the method comprising steps of administering the immunogenic composition of claim 1 to a subject in need thereof.

14. The method of claim 13 , wherein the immune response in the subject includes a humoral response.

15. The composition of claim 1 , wherein the core consists of the polypeptide consisting of the self-assembling Gag protein.

Assignments (4)
SECURITY INTEREST Recorded Jul 20, 2023
From: VARIATION BIOTECHNOLOGIES INC.
To: K2 HEALTHVENTURES LLC, AS CANADIAN COLLATERAL AGENT
Reel/Frame 064325/0840 →
RELEASE OF SECURITY INTEREST Recorded May 22, 2020
From: PCOF 1, LLC
To: VARIATION BIOTECHNOLOGIES (US), INC.; VBI VACCINES (DELAWARE), INC.; VARIATION BIOTECHNOLOGIES INC.
Reel/Frame 052744/0622 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2016
From: KLATZMANN, DAVID; BELLIER, BERTRAND; SALZMANN, JEAN-LOUP; FRIBERT, CHARLOTTE; COSSET, FRANCOIS-LOIC
To: L'UNIVERSITE PIERRE ET MARIE CURIE
Reel/Frame 038156/0409 →
SECURITY INTEREST Recorded Aug 8, 2014
From: VARIATION BIOTECHNOLOGIES (US), INC.; VBI VACCINES, INC.; VARIATION BIOTECHNOLOGIES INC.
To: PCOF 1, LLC
Reel/Frame 033501/0329 →